{
    "id": "34e9a6b6-450b-7d20-e063-6294a90ac831",
    "indications": "glimepiride tablets indicated adjunct diet exercise improve glycemic control adults type 2 diabetes mellitus [ ( 14.1 ) ] . limitations glimepiride tablets used treatment type 1 diabetes mellitus diabetic ketoacidosis , would effective settings .",
    "contraindications": "recommended starting dose 1 2 mg daily . increase 1 2 mg increments frequently every 1 2 weeks based glycemic response . maximum recommended dose 8 mg daily . ( 2.1 ) administer breakfast first meal day . ( 2.1 ) 1 mg starting dose titrate slowly patients increased risk hypoglycemia ( e.g . , elderly , patients renal impairment ) . ( 2.1 )",
    "warningsAndPrecautions": "glimepiride tablets usp available following strengths package sizes : 1 mg ( light pink colored , flat capsule shaped uncoated tablets break line faces gm 1 engraved either side breakline one face . ) bottles 100 ( ndc 42571-100-01 ) bottles 500 ( ndc 42571-100-05 ) 2 mg ( light green colored , flat capsule shaped uncoated matt finished tablets break line faces gm 2 engraved either side breakline one face . ) bottles 100 ( ndc 42571-101-01 ) bottles 500 ( ndc 42571-101-05 ) 3 mg ( pale yellow colored , flat capsule shaped uncoated tablets breakline faces gm 3 engraved either side breakline one face . ) bottles 100 ( ndc 42571-102-01 ) bottles 500 ( ndc 42571-102-05 ) 4 mg ( light blue colored , flat capsule shaped uncoated matt finished tablets break line faces gm 4 engraved either side breakline one face . ) bottles 100 ( ndc 42571-103-01 ) bottles 500 ( ndc 42571-103-05 ) 6 mg ( brick red colored , flat capsule shaped uncoated tablets breakline faces gm 6 engraved either side breakline one face . ) bottles 100 ( ndc 42571-104-01 ) bottles 500 ( ndc 42571-104-05 ) 8 mg ( white white , flat capsule shaped uncoated tablets breakline faces gm 8 engraved either side breakline one face . ) bottles 100 ( ndc 42571-105-01 ) bottles 500 ( ndc 42571-105-05 ) store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense well-closed containers safety closures .",
    "adverseReactions": "glimepiride tablets contraindicated patients history hypersensitivity reaction : glimepiride product ’ ingredients [ ( 5.2 ) ] . sulfonamide derivatives : patients developed allergic reaction sulfonamide derivatives may develop allergic reaction glimepiride tablets . glimepiride tablets patients history allergic reaction sulfonamide derivatives .",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "GLIMEPIRIDE",
            "code": "6KY687524K"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Micro Labs Limited",
    "name": "Glimepiride",
    "effectiveTime": "20250512",
    "indications_original": "Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus\n \n  [see\n                     \n                        Clinical Studies (14.1)\n                     \n                     ].\n                  \n                  \n                     \n                        Limitations of Use\n                     \n                      \n                  \n                  \n                  Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.",
    "contraindications_original": "Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. ( 2.1 ) Administer with breakfast or first meal of the day. ( 2.1 ) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). ( 2.1 )",
    "warningsAndPrecautions_original": "Glimepiride Tablets USP are available in the following strengths and package sizes:\n                  \n                  \n                     1 mg (Light pink colored, flat capsule shaped uncoated tablets having break line on both faces and GM and 1 on engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-100-01)\n                     Bottles of 500 (NDC 42571-100-05)\n                  \n                  \n                  \n                     2 mg (Light green colored, flat capsule shaped uncoated matt finished tablets having break line on both faces and GM and 2 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-101-01)\n                     Bottles of 500 (NDC 42571-101-05)\n                  \n                  \n                  \n                     3 mg (Pale yellow colored, flat capsule shaped uncoated tablets having breakline on both faces and GM and 3 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-102-01)\n                     Bottles of 500 (NDC 42571-102-05)\n                  \n                  \n                  \n                     4 mg (Light blue colored, flat capsule shaped uncoated matt finished tablets having break line on both faces and GM and 4 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-103-01)\n                     Bottles of 500 (NDC 42571-103-05)\n                  \n                  \n                  \n                     6 mg (Brick red colored, flat capsule shaped uncoated tablets having breakline on both faces and GM and 6 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-104-01)\n                     Bottles of 500 (NDC 42571-104-05)\n                  \n                  \n                  \n                     8 mg (White to off white, flat capsule shaped uncoated tablets having breakline on both faces and GM and 8 engraved on either side of breakline on one face.)\n                  \n                  \n                  \n                     Bottles of 100 (NDC 42571-105-01)\n                     Bottles of 500 (NDC 42571-105-05)\n                  \n                  \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in well-closed containers with safety closures.",
    "adverseReactions_original": "Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to:\n                  \n                  \n                     Glimepiride or any of the product’s ingredients\n  \n   [see\n   \n    Warnings and Precautions (5.2)].\n  \n   \n                     \n                     Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride tablets. Do not use glimepiride tablets in patients who have a history of an allergic reaction to sulfonamide derivatives."
}